 |
17 Diseases |  |
9 Trials |
|
9 Trials |  |
424 News |  |
| «123456» |
- | Fosrenol (lanthanum carbonate) / Takeda, NN1213 / Novo Nordisk
Phase classification, Trial completion date, Trial primary completion date: The COMBINE Study: The CKD Optimal Management With BInders and NicotinamidE (clinicaltrials.gov) - Apr 19, 2019
P2, N=205, Active, not recruiting, Sponsor: Jennifer Gassman, PhD
Phase classification: P3 --> P2 | Trial completion date: Jun 2018 --> Sep 2019 | Trial primary completion date: May 2018 --> Nov 2018
- | Fosrenol (lanthanum carbonate) / Takeda
Clinical, Journal: Relationship between Gut Microbiota and Phosphorus Metabolism in Hemodialysis Patients: A Preliminary Exploration. (Pubmed Central) - Apr 17, 2019
Gut flora related to phosphorus metabolism in hemodialysis patients, and improving intestinal microbiota may regulate the absorption of phosphate in the intestine. The use of phosphate binder lanthanum carbonate leads to a tendency of decreasing microbial diversity and lower network complexity.
- | Fosrenol (lanthanum carbonate) / Takeda
Retrospective data, Journal: A meta-analysis of phosphate binders lanthanum carbonate versus sevelamer hydrochloride in patients with end-stage renal disease undergoing hemodialysis. (Pubmed Central) - Apr 9, 2019
SH treatment of patients with ESRD is more effective compared to LC treatment. However, more well-designed random control trails are required for confirmation.
- | Renagel (sevelamer) / Sanofi, Kiklin (bixalomer) / Astellas, Fosrenol (lanthanum carbonate) / Takeda
Journal: Phosphate Binders Derived from Natural Ores Contain Many Kinds of Metallic Elements Besides Their Active Ingredient Metals. (Pubmed Central) - Mar 27, 2019
However, it should be emphasized that patients undergoing dialysis do not have a urinary excretion route and are administered many phosphate binder pills every day over a long period of time. In the future, pharmaceutical companies may have to disclose standard amounts and/or analytical values regarding the type and quantity of metallic elements in the final formulation or pharmaceutical bulk derived from natural ores.
- || Fosrenol (lanthanum carbonate) / Takeda
Enrollment closed, Trial completion date, Trial primary completion date: A Study to Assess the Pharmacokinetics of Lanthanum Carbonate, Investigate and Compare the Efficacy, Safety and Tolerability of Lanthanum Carbonate With Calcium Carbonate in Hyperphosphataemic Children and Adolescents With Chronic Kidney Disease on Dialysis (clinicaltrials.gov) - Nov 7, 2018
P2, N=63, Active, not recruiting, Sponsor: Shire
In the future, pharmaceutical companies may have to disclose standard amounts and/or analytical values regarding the type and quantity of metallic elements in the final formulation or pharmaceutical bulk derived from natural ores. Recruiting --> Active, not recruiting | Trial completion date: Jul 2018 --> Feb 2019 | Trial primary completion date: Jul 2018 --> Feb 2019
- | Fosrenol (lanthanum carbonate) / Takeda
Trial completion date: FOSRENOL-HD: Fosrenol Post-marketing Surveillance for Hemodialysis in Japan (clinicaltrials.gov) - Sep 27, 2018
P=N/A, N=3267, Active, not recruiting, Sponsor: Bayer
Recruiting --> Active, not recruiting | Trial completion date: Jul 2018 --> Feb 2019 | Trial primary completion date: Jul 2018 --> Feb 2019 Trial completion date: Dec 2018 --> Jun 2019
- | Fosrenol (lanthanum carbonate) / Takeda
Trial completion date, Trial primary completion date: Outcome Study of Lanthanum Carbonate Compared With Calcium Carbonate in Hemodialysis Patients : Landmark Study (clinicaltrials.gov) - Sep 17, 2018
P3, N=2309, Active, not recruiting, Sponsor: Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Trial completion date: Dec 2018 --> Jun 2019 Trial completion date: Jul 2018 --> Feb 2019 | Trial primary completion date: Jul 2018 --> Feb 2019
- || Fosrenol (lanthanum carbonate) / Takeda
Trial primary completion date: LAVALIER: Lanthanum Versus Calcium Carbonate for Vascular Abnormalities in Patients With CKD and Hyperphosphatemia (clinicaltrials.gov) - Aug 31, 2018
P4, N=60, Enrolling by invitation, Sponsor: Osaka University
Trial completion date: Jul 2018 --> Feb 2019 | Trial primary completion date: Jul 2018 --> Feb 2019 Trial primary completion date: Dec 2018 --> Dec 2020
- | Fosrenol (lanthanum carbonate) / Takeda
Clinical, Journal: Changes With Lanthanum Carbonate, Calcium Acetate, and Phosphorus Restriction in CKD: A Randomized Controlled Trial. (Pubmed Central) - Jul 12, 2018
P3
A 1-year intervention to limit phosphorus absorption using dietary restriction or 2 different phosphorus binders resulted in decreased bALP suggesting improved bone turnover, but no other significant changes in biochemical or vascular parameters in patients with CKD stage 3/4. (ClinicalTrials.gov: NCT01357317).
- | Fosrenol (lanthanum carbonate) / Takeda
Trial completion date, Trial primary completion date: Outcome Study of Lanthanum Carbonate Compared With Calcium Carbonate in Hemodialysis Patients : Landmark Study (clinicaltrials.gov) - May 3, 2018
P3, N=2309, Active, not recruiting, Sponsor: Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
(ClinicalTrials.gov: NCT01357317). Trial completion date: Jun 2017 --> Jul 2018 | Trial primary completion date: Jun 2017 --> Jul 2018
- || Fosrenol (lanthanum carbonate) / Takeda
Phase classification: FOSRENOL-HD: Fosrenol Post-marketing Surveillance for Hemodialysis in Japan (clinicaltrials.gov) - Apr 3, 2018
P, N=3267, Active, not recruiting, Sponsor: Bayer
Trial completion date: Jun 2017 --> Jul 2018 | Trial primary completion date: Jun 2017 --> Jul 2018 Phase classification: P=N/A --> P
- | Fosrenol (lanthanum carbonate) / Takeda
Clinical, Journal: Effect of high-protein meals during hemodialysis combined with lanthanum carbonate in hypoalbuminemic dialysis patients: findings from the FrEDI randomized controlled trial. (Pubmed Central) - Mar 25, 2018
Phase classification: P=N/A --> P In hypoalbuminemic hemodialysis patients, high-protein meals during dialysis combined with lanthanum carbonate are safe and increase serum albumin while controlling phosphorus.
- | Fosrenol (lanthanum carbonate) / Takeda
New P4 trial, Metastases: Different Effects of Non-calcium Phosphate Binders on Serum Calcium (clinicaltrials.gov) - Mar 1, 2018
P4, N=34, Completed, Sponsor: Medical Universtity of Lodz
- | Fosrenol (lanthanum carbonate) / Takeda
Phase classification: FOSRENOL-CAPD: Fosrenol Post-marketing Surveillance for Continuous Cyclic Peritoneal Dialysis in Japan (clinicaltrials.gov) - Jan 19, 2018
P=N/A, N=446, Completed, Sponsor: Bayer
In hypoalbuminemic hemodialysis patients, high-protein meals during dialysis combined with lanthanum carbonate are safe and increase serum albumin while controlling phosphorus. Phase classification: P4 --> P=N/A
- | Fosrenol (lanthanum carbonate) / Takeda
Trial completion, Enrollment change, Trial primary completion date: Healthy Combine Study (clinicaltrials.gov) - Dec 22, 2017
P1, N=39, Completed, Sponsor: Northwestern University
Phase classification: P4 --> P=N/A Recruiting --> Completed | N=80 --> 39 | Trial primary completion date: Dec 2018 --> Dec 2017
- | Fosrenol (lanthanum carbonate) / Takeda
New P3 trial: LaCa: Lanthanum Carbonate (Fosrenol (clinicaltrials.gov) - Nov 17, 2017
P3, N=35, Recruiting, Sponsor: Universitair Ziekenhuis Brussel
- | Fosrenol (lanthanum carbonate) / Takeda
Trial primary completion date: Fosrenol and Phosphorus Balance - Lanthanum Carbonate (clinicaltrials.gov) - May 9, 2017
P=N/A, N=9, Completed, Sponsor: Los Angeles Biomedical Research Institute
Recruiting --> Completed | N=80 --> 39 | Trial primary completion date: Dec 2018 --> Dec 2017 Trial primary completion date: Jun 2014 --> May 2017
- | Fosrenol (lanthanum carbonate) / Takeda
New P1 trial: Bioequivalence Study of BAY 77-1931 Orally Disintegrating Tablet (clinicaltrials.gov) - Mar 8, 2017
P1, N=20, Completed, Sponsor: Bayer
- Fosrenol (lanthanum carbonate) / Takeda
Trial primary completion date: A Study to Assess the Pharmacokinetics of Lanthanum Carbonate, Investigate and Compare the Efficacy, Safety and Tolerability of Lanthanum Carbonate With Calcium Carbonate in Hyperphosphataemic Children and Adolescents With Chronic Kidney Disease on Dialysis (clinicaltrials.gov) - Jan 26, 2017
P2, N=50, Recruiting, Sponsor: Shire
Trial primary completion date: Jun 2014 --> May 2017 Trial primary completion date: Mar 2017 --> Jul 2018
- | Evrenzo (roxadustat) / Astellas, AstraZeneca, FibroGen
Trial completion, Trial primary completion date: A Drug Interaction Study to Evaluate the Pharmacokinetics of ASP1517 and Lanthanum Carbonate Hydrate (clinicaltrials.gov) - Jan 26, 2017
P1, N=18, Completed, Sponsor: Astellas Pharma Inc
Trial primary completion date: Mar 2017 --> Jul 2018 Recruiting --> Completed | Trial primary completion date: Mar 2017 --> Dec 2016
- | Fosrenol (lanthanum carbonate) / Takeda
Enrollment closed: The COMBINE Study: The CKD Optimal Management With BInders and NicotinamidE (clinicaltrials.gov) - Dec 28, 2016
P3, N=205, Active, not recruiting, Sponsor: John Kusek
Recruiting --> Completed | Trial primary completion date: Mar 2017 --> Dec 2016 Recruiting --> Active, not recruiting
- Evrenzo (roxadustat) / Astellas, AstraZeneca, FibroGen
Enrollment open: A Drug Interaction Study to Evaluate the Pharmacokinetics of ASP1517 and Lanthanum Carbonate Hydrate (clinicaltrials.gov) - Dec 12, 2016
P1, N=18, Recruiting, Sponsor: Astellas Pharma Inc
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||| Fosrenol (lanthanum carbonate) / Takeda
Trial completion: Fosrenol Post-marketing Surveillance in Japan (clinicaltrials.gov) - Dec 8, 2016
P=N/A, N=343, Completed, Sponsor: Bayer
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- || Fosrenol (lanthanum carbonate) / Takeda
Enrollment closed, Trial primary completion date: FOSRENOL-HD: Fosrenol Post-marketing Surveillance for Hemodialysis in Japan (clinicaltrials.gov) - Dec 7, 2016
P=N/A, N=3267, Active, not recruiting, Sponsor: Bayer
Active, not recruiting --> Completed Trial primary completion date: Mar 2016 --> Dec 2018 | Completed --> Active, not recruiting
- | Fosrenol (lanthanum carbonate) / Takeda
Phase classification: FOSRENOL-CAPD: Fosrenol Post-marketing Surveillance for Continuous Cyclic Peritoneal Dialysis in Japan (clinicaltrials.gov) - Dec 7, 2016
P4, N=446, Completed, Sponsor: Bayer
Trial primary completion date: Mar 2016 --> Dec 2018 | Completed --> Active, not recruiting Phase classification: P=N/A --> P4
- | Evrenzo (roxadustat) / Astellas, AstraZeneca, FibroGen
New P1 trial: A Drug Interaction Study to Evaluate the Pharmacokinetics of ASP1517 and Lanthanum Carbonate Hydrate (clinicaltrials.gov) - Nov 2, 2016
P1, N=18, Not yet recruiting, Sponsor: Astellas Pharma Inc
- ||| Fosrenol (lanthanum carbonate) / Takeda
Trial completion, Enrollment change: FOSRENOL-CAPD: Fosrenol Post-marketing Surveillance for Continuous Cyclic Peritoneal Dialysis in Japan (clinicaltrials.gov) - Oct 26, 2016
P=N/A, N=446, Completed, Sponsor: Bayer
Phase classification: P=N/A --> P4 Active, not recruiting --> Completed | N=3000 --> 446
- || Fosrenol (lanthanum carbonate) / Takeda
Trial primary completion date: LAVALIER: Lanthanum Versus Calcium Carbonate for Vascular Abnormalities in Patients With CKD and Hyperphosphatemia (clinicaltrials.gov) - Sep 27, 2016
P4, N=60, Enrolling by invitation, Sponsor: Osaka University
Active, not recruiting --> Completed | N=3000 --> 446 Trial primary completion date: Dec 2017 --> Dec 2018
- || Fosrenol (lanthanum carbonate) / Takeda
Enrollment closed, Trial primary completion date: Fosrenol Post-marketing Surveillance in Japan (clinicaltrials.gov) - Jun 22, 2016
P=N/A, N=343, Active, not recruiting, Sponsor: Bayer
Trial primary completion date: Dec 2017 --> Dec 2018 Recruiting --> Active, not recruiting | Trial primary completion date: May 2016 --> Feb 2016
- ||| Fosrenol (lanthanum carbonate) / Takeda
Trial completion: Long Term Treatment of End Stage Renal Disease Patients With Lanthanum Carbonate (Fosrenol) (clinicaltrials.gov) - Jun 16, 2016
P=N/A, N=2105, Completed, Sponsor: Shire
Recruiting --> Active, not recruiting | Trial primary completion date: May 2016 --> Feb 2016 Active, not recruiting --> Completed
- || Fosrenol (lanthanum carbonate) / Takeda
Enrollment closed: FOSRENOL-HD: Fosrenol Post-marketing Surveillance for Hemodialysis in Japan (clinicaltrials.gov) - Mar 11, 2016
P=N/A, N=3267, Active, not recruiting, Sponsor: Bayer
Active, not recruiting --> Completed Completed --> Active, not recruiting
- ||| Fosrenol (lanthanum carbonate) / Takeda
Trial completion: FOSRENOL-HD: Fosrenol Post-marketing Surveillance for Hemodialysis in Japan (clinicaltrials.gov) - Feb 5, 2016
P=N/A, N=3267, Completed, Sponsor: Bayer
Completed --> Active, not recruiting Active, not recruiting --> Completed
- Fosrenol (lanthanum carbonate) / Takeda
Trial primary completion date: A Study to Assess the Pharmacokinetics of Lanthanum Carbonate, Investigate and Compare the Efficacy, Safety and Tolerability of Lanthanum Carbonate With Calcium Carbonate in Hyperphosphataemic Children and Adolescents With Chronic Kidney Disease on Dialysis (clinicaltrials.gov) - Feb 3, 2016
P2, N=50, Recruiting, Sponsor: Shire
Active, not recruiting --> Completed Trial primary completion date: Dec 2015 --> Mar 2017
- || Fosrenol (lanthanum carbonate) / Takeda
Enrollment closed: FOSRENOL-HD: Fosrenol Post-marketing Surveillance for Hemodialysis in Japan (clinicaltrials.gov) - Nov 16, 2015
P=N/A, N=3267, Active, not recruiting, Sponsor: Bayer
Trial primary completion date: Dec 2015 --> Mar 2017 Recruiting --> Active, not recruiting
- Fosrenol (lanthanum carbonate) / Takeda
Trial primary completion date: Phosphate Lowering in CKD Trial (clinicaltrials.gov) - Oct 22, 2015
P4, N=60, Recruiting, Sponsor: VA Office of Research and Development
Recruiting --> Active, not recruiting Trial primary completion date: Mar 2016 --> Mar 2019
- Maalox (aluminum hydroxide/simethicone/magnesium hydroxide) / Sanofi, Auryxia (ferric citrate) / Akebia Therap, Fosrenol (lanthanum carbonate) / Takeda
Enrollment open, Trial initiation date, Trial primary completion date: Optimal Anemia Treatment in End Stage Renal Disease (ERSD) (clinicaltrials.gov) - Sep 16, 2015
P=N/A, N=50, Recruiting, Sponsor: Azienda Ospedaliera Sant'Anna
Trial primary completion date: Mar 2016 --> Mar 2019 Not yet recruiting --> Recruiting | Initiation date: Nov 2014 --> Mar 2015 | Trial primary completion date: May 2016 --> Dec 2016
- || Fosrenol (lanthanum carbonate) / Takeda
Trial primary completion date: FOSRENOL-HD: Fosrenol Post-marketing Surveillance for Hemodialysis in Japan (clinicaltrials.gov) - Aug 20, 2015
P=N/A, N=3000, Recruiting, Sponsor: Bayer
Not yet recruiting --> Recruiting | Initiation date: Nov 2014 --> Mar 2015 | Trial primary completion date: May 2016 --> Dec 2016 Trial primary completion date: Oct 2016 --> Dec 2015
- |||| Fosrenol (lanthanum carbonate) / Takeda
Enrollment open: LAVALIER: Lanthanum Versus Calcium Carbonate for Vascular Abnormalities in Patients With CKD and Hyperphosphatemia (clinicaltrials.gov) - Apr 21, 2015
P4, N=60, Enrolling by invitation, Sponsor: Osaka University
Trial primary completion date: Oct 2016 --> Dec 2015 Not yet recruiting --> Enrolling by invitation
- | Fosrenol (lanthanum carbonate) / Takeda
Enrollment open: The COMBINE Study: The CKD Optimal Management With BInders and NicotinamidE (clinicaltrials.gov) - Mar 31, 2015
P3, N=200, Recruiting, Sponsor: John Kusek
Not yet recruiting --> Enrolling by invitation Not yet recruiting --> Recruiting
- Fosrenol (lanthanum carbonate) / Takeda
Enrollment open: Phosphate Lowering in CKD Trial (clinicaltrials.gov) - Mar 24, 2015
P4, N=60, Recruiting, Sponsor: Department of Veterans Affairs
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Maalox (aluminum hydroxide/simethicone/magnesium hydroxide) / Sanofi, Auryxia (ferric citrate) / Japan Tobacco, Akebia Therap, Fosrenol (lanthanum carbonate) / Takeda
Clinical: Optimal Anemia Treatment in End Stage Renal Disease (ERSD) (clinicaltrials.gov) - Oct 24, 2014
P=N/A, N=50, Not yet recruiting, Sponsor: Azienda Ospedaliera Sant'Anna
- || Fosrenol (lanthanum carbonate) / Takeda
New P3 trial: The COMBINE Study: The CKD Optimal Management With BInders and NicotinamidE (clinicaltrials.gov) - Oct 10, 2014
P3, N=200, Not yet recruiting, Sponsor: John Kusek
- | Fosrenol (lanthanum carbonate) / Takeda
New P4 trial: LAVALIER: Lanthanum Versus Calcium Carbonate for Vascular Abnormalities in Patients With CKD and Hyperphosphatemia (clinicaltrials.gov) - Sep 11, 2014
P4, N=60, Not yet recruiting, Sponsor: Osaka University
- | Fosrenol (lanthanum carbonate) / Takeda
Enrollment closed, Enrollment change: Outcome Study of Lanthanum Carbonate Compared With Calcium Carbonate in Hemodialysis Patients : Landmark Study (clinicaltrials.gov) - Aug 22, 2014
P3, N=2309, Active, not recruiting, Sponsor: Translational Research Informatics Center, Kobe, Hyogo, Japan
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | N=3000 --> 2309
- || Fosrenol (lanthanum carbonate) / Takeda
Enrollment closed, Trial primary completion date: FOSRENOL-CAPD: Fosrenol Post-marketing Surveillance for Continuous Cyclic Peritoneal Dialysis in Japan (clinicaltrials.gov) - Aug 12, 2014
P=N/A, N=3000, Active, not recruiting, Sponsor: Bayer
Recruiting --> Active, not recruiting | N=3000 --> 2309 Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2016 --> Apr 2014
- | Fosrenol (lanthanum carbonate) / Takeda
New P4 trial: Phosphate Lowering in CKD Trial (clinicaltrials.gov) - Aug 6, 2014
P4, N=60, Not yet recruiting, Sponsor: Department of Veterans Affairs
- Fosrenol (lanthanum carbonate) / Takeda
Trial primary completion date: Efficacy of Lanthanum Carbonate in Calciphylaxis (clinicaltrials.gov) - May 18, 2014
P1, N=12, Completed, Sponsor: University of Wisconsin, Madison
Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2016 --> Apr 2014 Trial primary completion date: Nov 2012 --> Mar 2013
- Fosrenol (lanthanum carbonate) / Takeda
Trial completion date: Efficacy of Lanthanum Carbonate in Calciphylaxis (clinicaltrials.gov) - May 18, 2014
P1, N=12, Completed, Sponsor: University of Wisconsin, Madison
Trial primary completion date: Nov 2012 --> Mar 2013 Trial completion date: Feb 2013 --> May 2013
- | Fosrenol (lanthanum carbonate) / Takeda
Trial completion: Efficacy of Lanthanum Carbonate in Calciphylaxis (clinicaltrials.gov) - May 18, 2014
P1, N=12, Completed, Sponsor: University of Wisconsin, Madison
Trial completion date: Feb 2013 --> May 2013 Recruiting --> Completed
- | Fosrenol (lanthanum carbonate) / Takeda
Enrollment change: A Study to Assess the Pharmacokinetics of Lanthanum Carbonate, Investigate and Compare the Efficacy, Safety and Tolerability of Lanthanum Carbonate With Calcium Carbonate in Hyperphosphataemic Children and Adolescents With Chronic Kidney Disease on Dialysis (clinicaltrials.gov) - Apr 28, 2014
P2, N=50, Recruiting, Sponsor: Shire
Recruiting --> Completed N=100 --> 50